Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. engages in the development and commercialization of controlled release combination therapeutics to treat healthcare problems, primarily in the areas of infectious diseases and central nervous system disorders. It also develops novel extended release and combination products for symptomatic treatment of dementia. The company was incorporated in 2000 and is headquartered in Emeryville, California with operations in India, the United States, and Singapore.

EMERYVILLE, Calif., March  06, 2020  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted six new employees the option to purchase an aggregate of 70,000 shares of the company’s common stock, at a per share exercise price of $3.89, the closing trading price on March 6, and restricted stock units to acquire 35,000 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Adamas Announces  New Employment Inducement Grant

Adamas Pharmaceuticals, Inc.'s (ADMS) CEO Neil McFarlane on Q4 2019 Results - Earnings Call Transcript

-  Final results reported from the longest-running clinical trial of an amantadine product in Parkinson’s disease

Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinson’s Disease

EMERYVILLE, Calif., Jan.  10, 2020  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 12,000 shares of the company’s common stock, at a per share exercise price of $5.11, the closing trading price on January 8, and restricted stock units to acquire 6,000 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Adamas  Announces  New Employment Inducement Grant

-- Product sales expected to be approximately $16.3 million for fourth quarter 2019 and approximately $54.6 million for full year 2019 --    -- Total prescriptions of approximately 7,160 for fourth quarter 2019 and approximately 25,780 for full year 2019 --

Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020

- Adamas grants Sandoz license for its generic version of GOCOVRI® as of March 4, 2030 – over 12 years post GOCOVRI launch - - Adamas grants Sandoz license for its generic version of GOCOVRI® as of March 4, 2030 – over 12 years post GOCOVRI launch - 

Adamas Announces Settlement of Patent Litigation with Sandoz Inc.

Adamas: INROADS Data Sell-Off Goes Too Far

ABIOMED

ANGI Homeservices

DXC Technology

Kraft Heinz

Macy's

PG&E

Pfizer

TripAdvisor

Walgreens

Despite a continuation of the stock market bull run, there were a bunch of underperformers this year, including Macy's, TripAdvisor and Abiomed.

10 Worst-Performing Stocks of 2019

- INROADS study achieved its primary endpoint (proportion of responders with at least a 20% improvement from baseline to Week 12) -

Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking Impairment

EMERYVILLE, Calif., Dec.  09, 2019  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 89,000 shares of the company’s common stock, at a per share exercise price of $6.48, the closing trading price on December 6, and restricted stock units to acquire 44,500 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Adamas Announces New Employment Inducement Grant.

Adamas Pharmaceuticals: INROADS Data Will Make Or Break 2019

EMERYVILLE, Calif., Nov.  21, 2019  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the following investor conferences:

Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences

Adamas Pharmaceuticals, Inc. (ADMS) CEO Neil McFarlane on Q3 2019 Results - Earnings Call Transcript

Adamas (ADMS) delivered earnings and revenue surprises of -10.00% and -2.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Adamas Pharmaceuticals (ADMS) Reports Q3 Loss, Lags Revenue Estimates

Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

EMERYVILLE, Calif., Sept.  27, 2019  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the following investor conference:

Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference

EMERYVILLE, Calif., Sept.  20, 2019  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, announced today the presentation of new data on GOCOVRI® (amantadine) extended release capsules for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy at the Movement Disorder Society (MDS) 2019 International Congress, September 22-26, 2019 in Nice, France. The poster presentations will highlight data derived from the GOCOVRI development program and post-marketing pharmacovigilance surveillance.

Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson’s Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress

Bellus Health Inc. is a clinical-stage biopharmaceutical company.

Buy Bellus Health Before It Hits The Nasdaq

- Gregory Went, Ph.D., Founder, transitions to a strategic advisory role

Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer

ADMS had a very strong performance in the run-up to its 2017 approval of GOCOVRI.

Adamas Pharmaceuticals: A Second Inning In Play

Adamas publicized a mixed earnings with a beat on EPS and a miss on revenues. The market accepted the earnings in contrast to previous earnings where the stock was decimated.

Adamas: Positive Reaction To Encouraging Q2 Earnings Report

Adamas Pharmaceuticals, Inc. (ADMS) CEO Gregory Went on Q2 2019 Results - Earnings Call Transcript

AmerisourceBergen

Arch Capital

AerCap Hlds

Top Ranked Momentum Stocks to Buy for July 8th

Top Ranked Momentum Stocks to Buy for July 8th 2019

As of late, it has definitely been a great time to be an investor Adamas Pharmaceuticals.

Will Adamas Pharmaceuticals Continue to Surge Higher?

Adamas (ADMS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News for Adamas Pharmaceuticals Stock (ADMS)